Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): David SH Bell Added: 3 years ago
Thiazolidinediones (TZD) and metformin lower cardiac risk factors, as do serum glucoses, and are therefore the best choice for initial therapy of type 2 diabetes. To choose between metformin and a thiazolidinedione is difficult because of the many benefits of both drugs. In most cases, a combination of metformin and a TZD is chosen, and this article describes the rationale for this decision. The… View more
Author(s): David SH Bell Added: 3 years ago
Thiazolidinediones (TZD) and metformin lower cardiac risk factors, as well as lowering serum glucoses, and are therefore the best choice for initial therapy of type 2 diabetes. To choose between metformin and a thiazolidinedione is difficult because of the many benefits of both drugs. In most cases, a combination of metformin and a TZD is chosen, and this article describes the rationale for this… View more
Author(s): Stuart W Zarich Added: 3 years ago
The clustering of cardiovascular (CV) risk factors associated with insulin is known as 'syndrome XÔÇÖ, the 'deadly quartetÔÇÖ, and 'dysmetabolic syndromeÔÇÖ among others. In addition to the clustering of obesity, hypertension (HTN), glucose intolerance, high triglycerides, and low high-density lipoprotein (HDL), other metabolic abnormalities have been associated with this syndrome, including… View more
Author(s): Gurushankar Govindarajan , James R Sowers , Craig S Stump Added: 3 years ago
There has been an increase in the prevalence of diabetes mellitus over the past 40 years, both in the US and worldwide. The worldwide prevalence of diabetes in 2000 was approximately 2.8% and is estimated to grow to 4.4% by 2030. This translates to a projected rise of diabetes from 171 million in 2000 to well over 350 million in 2030. The epidemic of diabetes will continue to rise as there is… View more
Author(s): Allen B King , Gary S Wolfe Added: 3 years ago
Excess cardiovascular disease (CVD) with diabetes has been recognized for some time. Among diabetic individuals, CVD accounts for >50% of all deaths, and stroke accounts for an additional 15%.1 Diabetic women are at particularly high risk of CVD; diabetes eliminates the well-described female advantage for coronary disease mortality.2 This is alarming since the prevalence of type 2 diabetes is… View more
Author(s): Carrie Eshelbrenner , Karina Vasquez , Liberty O Yanze , et al Added: 3 years ago
Cardiologists in general are strong advocates of evidence-based medicine, due to the critical nature of ischemic heart disease in patients. The use of up-to-date scientific evidence from research is paramount as the basis for making many medical decisions. There are three major advantages to using this approach. First, it offers some of the most objective ways to determine and maintain consistent… View more
Author(s): Francisco Lopez-Jimenez Added: 3 years ago
For many years, scientists and clinicians have recognized the association between several relatively common conditions such as hypertension, abnormal glucose metabolism (diabetes and other milder forms of glucose intolerance), and obesity. The observed association has also included other factors such as abnormal lipids (cholesterol and triglycerides), elevated uric acid, and microscopic amounts… View more
Author(s): Stephen Ku , Steven V Edelman Added: 3 years ago
Cardiovascular disease is an important cause of morbidity and mortality in patients with type 1 and especially type 2 diabetes mellitus.1,2 Data from prospective studies suggest that diabetes is associated with a two to fourfold excess risk of coronary heart disease and coronary death.3–5 It was therefore hoped that controlling hyperglycemia would reduce cardiovascular disease incidence and… View more
Job title: Professor of Diabetic Medicine
Professor Petrie graduated from Edinburgh University medical school in 1989. His early clinical training was in Glasgow followed by a PhD on insulin sensitivity and endothelial function (1997) and further clinical and postdoctoral training at the University of Glasgow. He was Reader in Diabetic Medicine at the University of Dundee from 2003 where he led the initiation and successful establishment… View more
Author(s): Sophia Zoungas , John Chalmers , Anushka Patel Added: 3 years ago
Summary of the ADVANCE Trial Findings The ADVANCE trial was a factorial, randomised study of 11,140 individuals with type 2 diabetes from over 200 collaborating centres in 20 countries from Asia, Australasia, Europe and North America. Participants with either a history of macrovascular or microvascular disease or at least one major risk factor for cardiovascular disease and any initial level of… View more